Research Paper Volume 14, Issue 8 pp 3365—3386
Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties
Figure 1. Illustration of TP53’s interactions with other signaling pathways important in regulation of cell growth and sites of interaction for chemotherapeutic drugs, certain signal transduction inhibitors, natural products and nutraceuticals. Green arrows = induction of a pathway, red arrows = suppression of a pathway.